| Names | |
|---|---|
| Preferred IUPAC name | 2',4'-difluoro-4-hydroxy-[1,1'-biphenyl]-3-carboxylic acid |
| Other names | Dolobid Dolocid Fluniget |
| Pronunciation | /daɪˈfluːnɪsæl/ |
| Identifiers | |
| CAS Number | 439-14-5 |
| Beilstein Reference | 136654 |
| ChEBI | CHEBI:4653 |
| ChEMBL | CHEMBL1505 |
| ChemSpider | 6267 |
| DrugBank | DB00861 |
| ECHA InfoCard | 100.034.436 |
| EC Number | 5.3.1.9 |
| Gmelin Reference | 95799 |
| KEGG | D00320 |
| MeSH | D013788 |
| PubChem CID | 3150 |
| RTECS number | DJ0480000 |
| UNII | 6PLQ3CP4P3 |
| UN number | UN3077 |
| Properties | |
| Chemical formula | C13H8F2O3 |
| Molar mass | 250.187 g/mol |
| Appearance | White to off-white, crystalline powder |
| Odor | Odorless |
| Density | 1.425 g/cm³ |
| Solubility in water | Slightly soluble |
| log P | 3.3 |
| Vapor pressure | 2.6 x 10^-7 mmHg |
| Acidity (pKa) | 3.54 |
| Basicity (pKb) | 13.96 |
| Magnetic susceptibility (χ) | -83.5×10⁻⁶ cm³/mol |
| Refractive index (nD) | 1.626 |
| Viscosity | Viscous |
| Dipole moment | 2.47 D |
| Thermochemistry | |
| Std molar entropy (S⦵298) | 248.6 J·mol⁻¹·K⁻¹ |
| Std enthalpy of formation (ΔfH⦵298) | -348.2 kJ/mol |
| Std enthalpy of combustion (ΔcH⦵298) | -5124 kJ/mol |
| Pharmacology | |
| ATC code | M01AB05 |
| Hazards | |
| Main hazards | May cause allergic reactions, gastrointestinal bleeding, kidney dysfunction, and increased risk of cardiovascular events. |
| GHS labelling | GHS labelling: `"Warning; H302; H315; H319; H335"` |
| Pictograms | ❌💉 🚫🧒 ⚠️🤰 🚫🍺 |
| Signal word | Warning |
| Hazard statements | H302 + H312 + H332: Harmful if swallowed, in contact with skin, or if inhaled. |
| Precautionary statements | Keep out of reach of children. If swallowed, get medical help or contact a Poison Control Center right away. |
| NFPA 704 (fire diamond) | 2-1-0 |
| Flash point | 196°C |
| Autoignition temperature | 550°C |
| Lethal dose or concentration | LD50 (oral, rat): 500 mg/kg |
| LD50 (median dose) | TDLo=810 mg/kg (oral, rat) |
| NIOSH | WT1600000 |
| PEL (Permissible) | 40 mg/m3 |
| REL (Recommended) | 0.38 |
| Related compounds | |
| Related compounds | Salicylic acid Aspirin Salsalate |
| Property | Industrial Manufacturer Commentary |
|---|---|
| Product Name & IUPAC Name |
Product Name: Diflunisal IUPAC Name: 2',4'-Difluoro-4-hydroxybiphenyl-3-carboxylic acid |
| Chemical Formula |
C13H8F2O3 The formula remains fixed for all grades, determined by the biphenyl and difluorinated substitution pattern. |
| Synonyms & Trade Names |
Synonyms include: 2',4'-Difluoro-4-hydroxybiphenyl-3-carboxylic acid, Dolobid. Trade names depend on regional licensing and regulatory approval; generic references typically use "Diflunisal". |
| HS Code & Customs Classification |
HS Code assignment uses: 29163900 (Aromatic carboxylic acids with additional oxygen function). Actual code can depend on country-specific customs interpretation or downstream formulation (API, finished form, or intermediate). |
Commercial-scale production relies on high-purity difluorobenzene and hydroxybenzoic acid derivatives as primary inputs. Material traceability back to primary manufacturers helps limit fluorinated aromatic side-product load. Impurity profile of starting materials determines downstream purification workload and impacts the total cost of goods.
Predominant synthesis route couples halogenated biphenyl systems using transition metal catalysts or via nucleophilic aromatic substitution. Process choice depends on availability of key intermediates and environmental constraints on by-product disposal. Fluorination route moderation is necessary to avoid over-fluorinated side species, which do not resolve easily during downstream purification.
In-process control focuses on:
Key impurities stem from incomplete fluorination, formation of polyfluorinated analogues, and overoxidation of the phenol group. Secondary pathway by-products can accumulate if raw material quality fluctuates. Process water and cleaning solvent residue must be managed to prevent cross-contamination during consecutive batches.
Standard industry practice applies multi-stage recrystallization for bulk intermediate isolation. Final API or high-purity grades pass through activated carbon and pH-specific filtration to strip organic and halide-bearing impurities. Selection of solvent system for final precipitation is crucial for downstream filtration efficiency and pressure drop management.
Analytical control employs HPLC, GC-MS, and NMR for batch identity and quantitative impurity profiling. Methods and acceptance ranges require tuning according to final grade specification, whether pharmaceutical or fine chemical.
Batch traceability is maintained through linking starting material lot codes with final product release reports. Each batch profile is re-verified to internal reference stocks to balance regulator expectations for batch-to-batch reproducibility. Out-of-trend results trigger root cause investigations, usually centered on intermediate crystallization parameters or raw material variance.
Detailed specifications can be defined according to the product grade. For pharmaceutical-grade Diflunisal, the final release standard is subject to internal quality control criteria and customer requirements, including limits for key related substances, heavy metals, and solvent residues.
Industrial-scale Diflunisal routinely presents as a white to off-white crystalline powder. Visual characteristics may shift slightly according to synthesis batch and particle size distribution. Commercial grades generally avoid pronounced odor; handling in bulk form does not emit noticeable fumes unless contaminated or degraded. Particle morphology and bulk density fluctuate depending on milling, drying, and sieving choices configured per downstream tableting or formulation needs.
Melting behavior is most sensitive to trace impurity levels and crystal habit. Pharmaceutical-accepted melting point ranges prompt additional purification if observed outside the established range. Boiling and flash points hold little technical relevance due to the compound’s decomposition prior to boiling; these values are seldom utilized in routine quality control protocols for this class of non-volatile solid APIs.
Bulk and tapped densities directly depend on crystallization solvent, drying regime, and particle treatment steps. These metrics inform blending, compaction, and packaging procedures for tablet and capsule manufacturing but are not static, as dust content and milling settings form significant variables batch to batch.
Avoid long exposure to elevated temperatures and uncontrolled humidity. Sensitivity to strong oxidizers and alkali bases prompts caution when handling in multipurpose facilities. Process scale-up experience shows no unexpected runaway reactions in validated production routes, though all raw materials are qualified to avoid contaminant-initiated side-reactions which could form colored or less soluble product forms.
Diflunisal demonstrates low aqueous solubility but dissolves freely in many polar organic solvents. Pharmaceutical and fine chemical applications frequently employ solvent-specific dissolution testing. Particle size reduction provides marginal improvement in dissolution. Solubility behavior should be confirmed for each intermediate and final step due to impact from solid form and polymorph, which varies across different crystallization and drying variants.
Final specification tables are defined according to customer application — e.g., pharmaceutical API, intermediate, research grade. Each may list individual content, related substances, appearance, water content, and residual solvent acceptance levels. Batch-specific certificate of analysis references internal reference standards and/or pharmacopeial monographs where applicable.
Process route selection dictates dominant impurity patterns; typical suspects include unreacted starting materials, process-related intermediates, and degradation-related byproducts. Patient safety and compliance with regulatory filings require intensive profiling and routine trend monitoring. Impurities of particular concern are tightly tracked during development and scale-up runs, especially those under regulatory scrutiny or those that have shown prior unexpected increases post-tech transfer or scale change.
HPLC serves as primary assay and related substances platform. Method validation includes specificity, repeatability, and detection limit studies tailored to the grade and final application. Raw material screening, in-process controls, and release testing procedures are all coordinated under GMP guidance wherever pharmaceutical use is claimed. Testing is harmonized with major pharmacopeias where possible; otherwise, internal validated methods form the release criteria.
Precursor selection focuses on chemical purity, supply reliability, and cost impact. Specific attention is accorded to trace metal and halogen content from primary aromatic and acid starting materials, as these residues can affect product color and impurity levels in finished batches. Alternate sources may require revalidation of synthetic and purification steps to ensure process behavior matches original data.
Route choice typically centers on carboxylation and acylation reactions involving halogenated salicylic acid derivatives under specific catalyst and solvent regimes. Every route brings its own signature impurity risk, including positional isomers and overreaction byproducts. Continuous monitoring of key reaction parameters has proven the main safeguard against unwanted side product accumulation.
Neutralization steps, temperature profile adherence, and solvent removal rank as high-risk points for yield and quality deviations. Color changes and precipitation behavior receive real-time operator attention. Purification procedures (extraction, crystallization, filtration) adapt to impurity load and batch size, with mother liquor recycling assessed after every campaign to monitor material impact. Final product meets filterability and clarity standards set by internal technical teams in conjunction with customer requirements.
Batch records detail deviation management and hold criteria at all critical stages. Only batches that meet all pre-determined assay, related substance, identity, and appearance parameters achieve release to customers. In-process testing feedback loops often prompt small solvent or pH adjustments even within nominal process windows to maintain inter-batch consistency.
Diflunisal undergoes esterification and amidation in targeted modification work, producing intermediates relevant for both formulation and research uses. Sensitivity to acidic or basic conditions has practical impact during downstream synthetic steps as unwanted hydrolysis or rearrangement can occur if pH is not tightly regulated. Reactivity profile supports exploration in prodrug design and certain complexation chemistries for specialty product lines.
Catalyst and solvent systems shift according to target modification. Aromatic nucleophilic substitution and coupling reactions progress best with controlled heating and exclusion of moisture. Lab scale findings must be carefully scaled due to heat management and stirring efficacy limitations at industrial volume.
Product modification projects have led to sulfonate and amide derivatives for research and specialty pharmaceutical markets. Route selection for derivative synthesis is dictated by the desired end-use purity and pharmacological activity. Customer-driven requests often prompt pilot-scale runs to confirm impurity removal strategies can meet the expected purity profile.
Standard operating procedures recommend tight control over moisture ingress and temperature excursions. Storage in sealed, light-resistant containers mitigates degradation potential from photochemical and hydrolytic pathways discovered during long-term stability studies. Nitrogen overlay or desiccant packs may be adopted for sensitive grades meant for lengthy storage or global transport.
Material compatibility studies have confirmed inert plastic-lined fiber drums and high-density polyethylene containers provide adequate protection for bulk powder. Stainless steel or glass are used for intermediate storage in API suites, especially for audit and traceability reasons in GMP settings.
Shelf life depends on impurity buildup rate, initial grade, and packaging choice. Degradation typically manifests as changes in color, increase in related substances, or drop in assay. Any deviation from original appearance or rise in known degradation markers leads to immediate investigation according to internal stability protocols and, when required, remedial action with affected lots.
Classification, labeling, and packaging requirements are set by applicable national and international regulations based on toxicological assessment data. Current evidence identifies significant health hazards upon ingestion or prolonged exposure, as documented in published safety data sheets and hazard communication programs.
Labeling through the supply chain indicates the need for personal protective equipment in production and sampling areas. Dust generation during transfer, grinding, or packaging creates inhalation risk and justifies local exhaust and dust minimization practices. Accidental contact events prompt immediate decontamination and medical evaluation in accordance with facility SOPs.
Oral and dermal toxicity results are derived from both preclinical and regulatory documentation. Accidental inhalation or ingestion requires medical intervention. Occupational health programs monitor personnel for adverse effects as indicated by exposure tracking and biomonitoring studies where such are indicated for the process or job classification.
Operational exposure guidelines align with published occupational exposure limits, subject to process risk assessment. Engineering controls, personal protective equipment mandates, and routine workplace air sampling support risk mitigation. Training and supervision for handling practices ensure that safe limits are rarely approached as a matter of standard operational integrity in manufacturing and packaging lines.
Industry production of diflunisal relies on consistent raw material input and stable operational scheduling. Output volumes track closely with the grade required—pharmaceutical API and advanced intermediate lots are batch-verified using validated processes. Jainol or salicylic acid derivatives, sulfonation control, and late-stage purification sequences define available capacity more than nominal reactor size. Actual availability varies by lead batch commitments, export licensing, and local regulatory requirements; production allocation for each order is confirmed against both campaign sequence and cleaning validation intervals.
Lead times depend on current campaign cycles, typical for synthetic APIs where custom route steps require careful scheduling and full release checks. Most lots for global shipment face lead times reflecting both production campaign alignment and documented stability reserve testing. Minimum order quantity aligns with validated lot scales and customer release protocol: smaller MOQ is feasible for reference or development grade, but full GMP and commercial lots run at scales defined by reactor charge limits and validated cleaning protocols.
Bulk and commercial lots employ multi-layer PE liners inside fiber drums, rigid HDPE container sets, or custom-sealed laminate packs by grade. Clinical trial and pre-market volumes can use smaller inner packs, depending on downstream filling requirements. Protection from moisture and cross-contamination informs choice of packaging—cGMP lines utilize tamper-evidence features and validated cleaning for all primary packaging surfaces.
API-grade material moves under export-compliant packaging, suitable for stability and risk class according to ICH and local transit rules. Documentation requires full batch release support and chain-of-custody shipment. INCO terms (FOB, CIF, or DAP) depend on customer location and compliance trigger points. Payment terms range from Irrevocable LC for new partners to net 30/60 for established customers, subject to internal credit review.
Diflunisal production economics trace back to the volatility in key aromatics and sulfonation agents. Salicylic acid or substituted benzenes price swings translate directly to cost basis. Fluctuations arise from local supply chain disruptions, regulatory import actions on key intermediates, plant maintenance downtime, and force majeure events at upstream suppliers. Where multi-step synthesis requires high purity base chemicals, regional price surges can transmit sharply to finished cost, often lagging integrated supply cycles by a quarter.
API price differences stem from documented release purity, impurity profile, and handling certification. Regulatory audit trails and full GMP compliance require additional batch and documentation work, validated through multi-point release testing. Higher-purity lots, typically released for regulated market submission, include costs for extended impurity scouting and more stringent primary packaging. Secondary and technical grades use more flexible process controls, translating to lower cost per kg but sharply different certificate of analysis and release protocols.
Global diflunisal demand is concentrated in mature pharmaceutical markets, with a notable rise in custom synthesis and CDMO projects in Asia. US and EU maintain demand for regulatory-vetted, validated lots, strongly influencing supplier qualification procedures. India and China contribute high-volume intermediate and API output, especially with policy incentives and integrated raw material sourcing. Regional regulatory developments, particularly post-pandemic logistical challenges, occasionally create supply bottlenecks.
US and EU import channels enforce strict audit-driven qualification, prolonging lot release cycles and intensifying documentation spend. Japan’s regulatory expectations match those of the EU, pressing for detailed impurity and trace residue profiles alongside stability assurance. India and China have ramped up backward integration, compressing lead cycles but sometimes encountering force majeure delays from local environmental policies on chemical plant operation.
Industry forecasts signal prices staying volatile through 2026, driven by raw material swings and evolving regulatory requirements. Downward price pressure remains contingent on energy and precursor stabilization in Asia, while new compliance costs or local environmental controls may push costs up in India and China. API-grade market segmentation by certificate and QA rigor keeps premium differentials intact, though technical and off-grade volumes could face margin pressure as more capacity comes online post-regulatory harmonization. Data supporting these projections draws on historical trade statistics, regional customs clearance trends, and reported manufacturer campaign plans.
Forecasts and industry averages build from a synthesis of international customs data, audited supply contracts, and region-specific regulatory filings supplied through industry associations and market analytics partners. Quantitative estimates favor year-on-year variance analysis and do not assume linear trend extrapolation—shifts in price typically lag supply interventions by at least one quarter.
South and East Asia have renewed focus on green chemistry routes, with regional authorities introducing stricter oversight on waste management and solvent recovery in diflunisal manufacturing. European regulators stepped up import scrutiny for nitrosamine risk, leading to transitional batch testing for all incoming lots to the EU since late 2023.
Recent updates include wider adoption of ICH M7 and Q3D into batch release criteria by both US and European importers. Several Asia-based facilities underwent re-certification to accommodate expanded impurity control panels and enhanced trace residue documentation. Regulatory moves to harmonize specifications between US and EU resulted in more comprehensive documentation for batch release, including extended stability and cross-contamination risk profiles.
Suppliers have accelerated backward integration, securing upstream raw material contracts to buffer against spike events. Key manufacturers invested in automated in-process monitoring with expanded impurity mapping to handle regulatory upgrades. Cross-region warehousing strategies receive attention to reduce lead time variance and mitigate logistical delays from localized transport disruptions.
In industrial practice, Diflunisal mainly serves pharmaceutical manufacturing, research chemical production, and intermediate synthesis. The choice of grade directly influences its usability in oral solid dosage forms, topical preparations, and lab-scale studies, as well as specialty applications such as chemical reference materials. Each sector brings its own regulatory and quality demands, frequently driving differences in impurity thresholds, microbiological status, or solvent residue allowances.
| Application | Recommended Grade | Main Differentiating Factors |
|---|---|---|
| Active Pharmaceutical Ingredient (API, Human Use) | Pharma Grade | Purity profile, controlled impurities, validated documentation, traceability, consistent batch data, regulatory compliance |
| Veterinary Drug Use | Veterinary Pharma Grade | Species-appropriate impurity controls, allowable excipient compatibility, adapted release documents |
| Research & Development | Laboratory/Reagent Grade | Suitability for non-clinical testing, typical purity above 98%, lower documentation burden, batch-to-batch reproducibility |
| Intermediate or Synthesis Feedstock | Technical or Custom Grade | Functional performance, tolerance for selected impurities, cost/performance balance, optional in-process documentation |
For API production, end-users inspect heavy metals, genotoxic impurities, and solvent residues tightly, often requiring confirmation from validated analytical methods. In non-human use and intermediate scenarios, some impurity thresholds relax if downstream purification is planned, yet consistent physical characteristics like particle size or flowability remain important for batchwise blending and further conversion. Select customers request additional documentation, such as compliance with region-specific pharmacopeial monographs, on a batch-by-batch basis.
Before procurement, clarify whether the intended use targets regulated pharmaceutical products, veterinary formulations, chemical synthesis, or solely internal R&D. Strict regulatory or clinical applications typically exclude grades designed for industrial technical workflows, where impurity profiles or residual solvent status might vary.
Verify which pharmacopeial, cGMP, or local regulatory standards apply. For human or animal pharmaceutical use, pursue grades meeting explicit pharmacopoeia (USP, EP, JP, or regional monographs) as relevant. End-user auditing often includes inspection of the full supply chain and original batch release records, not just a certificate of analysis.
Assess the required impurity acceptance limits and any application-specific chemical purity metrics. High-purity grades involve layered purification and in-process controls; these batches undergo finished product testing against detailed, grade-specific release standards. Intermediate and custom applications may permit different impurity profiles, subject to downstream purification capabilities.
Project annual requirements and budget tolerances, which may influence both lot size and grade choice. High-grade production imposes additional analytical, documentation, and compliance costs. Where scale or economics dictate, some customers optimize by matching grade only as closely as strictly needed by their end regulatory or synthesis step.
For new formulas or unfamiliar processes, technical teams should qualify a production sample at bench or pilot scale. Inspection covers both chemical conformity (HPLC assay, impurity profile, moisture) and process fit (powder handling, dissolution, compatibility with excipients or solvents). Feedback from these trials guides final release and, where required, last-mile process adjustments on the manufacturer’s side to ensure reproducibility.
As a producer of diflunisal, raw material management and process consistency stay under the oversight of internal and external audit systems. Achieving and maintaining ISO-based quality management certification requires clear documentation of factory activities, material traceability, documented deviation investigations, and locked-down change management procedures. This allows for a demonstration of continuous process control to meet pharmaceutical and fine chemical supply expectations. Ongoing qualification exercises involve cross-referencing both customer feedback and regulatory notification updates to maintain alignment with market and safety developments.
Experience with diflunisal for regulated applications regularly necessitates provision of certificates tailored to customer or authority requests. This includes provision of GMP certification for grades intended for pharmaceutical intermediate use. Regional regulatory filings or export requirements call for documentation ranging from written confirmations, secondary audits, and, when in scope, validation of site-specific impurity profiles against pharmacopeial standards. Not every lot holds every certificate by default—often, certifications are granted as per order requirements and batch designation.
We produce comprehensive documentation, including but not limited to: Certificate of Analysis (CoA) for each dispatch batch, available process route diagrams, impurity control rationales, and detailed batch history upon request from audit customers. Stability data is compiled from accelerated and real-time testing protocols, and is provided according to grade and release mandate. Manufacturing process changes receive documented change control records, traceable and available during supplier audits or QP review. Analytical test methods—validated in-house and, if required, cross-referenced to pharmacopeial monographs—are routinely updated based on instrument calibration logs and method revalidation outcomes.
Our diflunisal production utilizes key process controls monitored by advanced statistical process control systems, ensuring output stability across forecasted and customized demands. Core intermediates are sourced by registered raw material suppliers with transparent traceability. The operational calendar schedules dedicated campaign slots for recurring customers, balancing against short-notice batch production for urgent orders. Contracted customers can arrange dedicated volume windows or opt for call-off supply programs, subject to plant maintenance and statutory downtime cycles.
Production output and quality remain linked to both reactor line occupancy optimization and raw material delivery scheduling. Process consistency is maintained by in-line monitoring at critical reaction and purification steps, with intermediate analyses referencing batch-to-batch trend data. Finished material warehousing offers both segregation by production date and shipment readiness within agreed shelf-life profiles, which can be matched to destination region logistics constraints.
Sample requests trigger internal batch separation, drawing from recent production runs reflecting designated process conditions. Each sample dispatch carries documentation specifying batch code, production route, expiry assignment based on lot data, and available analytical results. Extended sample requirements—such as additional impurity data sets or alternative solvent analyses—are fulfilled by laboratory reruns and supplemental reporting aligned with customer specification sheets. Standard review timelines depend on current audit and sampling queue volumes.
Business partnerships are structured to support both framework agreements and one-off procurement models. Core customers may propose exclusive slot allocation, multi-year call-off contracts, or rolling forecast delivery schedules, each reflecting precise volume brackets and target lead times. For project-based inquiries or market launches, pilot-plant runs and customized quality documentation packages can be initiated with up-front specification alignment. Coordination with customer procurement, QA, and technical departments ensures requirements for documentation, packaging, lot splitting, and delivery modalities are met without deviation from underlying quality management disciplines.
Research teams in manufacturing facilities continue to examine diflunisal for its use as a nonsteroidal anti-inflammatory drug (NSAID), especially in the context of analgesic and anti-inflammatory indications. Several pilot programs are evaluating solid-state modifications, such as salt or co-crystal formation, to optimize both compressibility and solubility, addressing specific challenges in tablet formulation relevant to pharmaceutical customers. Raw material selection for these R&D efforts centers on precursor purity, with supply chain traceability supported by audit trails for key aromatic starting materials.
Growing interest has developed around diflunisal as an amyloid disease modulator, primarily in early-stage studies targeting transthyretin polyneuropathy and cardiomyopathy. Production facilities responding to requests from these markets adjust particle size distribution and surface area. Specific modifications in synthesis or milling routes are usually defined in discussion with the lead researcher or technical client, given high sensitivity to batch-to-batch variability in specialty pharma and research settings.
Consistent polymorph control has posed recurring challenges during both scale-up and ongoing manufacturing. Direct feedback from solid-form screening campaigns has led to tailored process modifications, such as temperature and solvent progression adjustments, aimed at minimizing batch heterogeneity. Quality assurance protocols emphasize real-time in-process controls and advanced chromatographic method development, ensuring impurity levels—especially residual halogenated byproducts and particulate formation—align with project-specific specifications. When required, extra purification steps and high-resolution filtration safeguard downstream formulation compatibility.
Demand patterns reflect persistent requirements from both generic NSAID manufacturers and new research-based applications. Production planning incorporates multi-year customer framework agreements to absorb forecasted orders. Market volatility, driven by regulatory decisions and patent landscapes, is handled through flexible campaign scheduling and inventory buffers.
Continuous process improvements receive ongoing investment, with digitalization of batch records, implementation of process analytical technologies, and adaptation of synthesis modules for quick grade-switching. Select projects integrate closed-loop feedback during reaction stages, directly responding to analytical signals related to endpoint purity or undesired side reactions. Downstream, tighter granulation and drying controls minimize lot-to-lot variability, with batch release criteria anchored by both compendial and bespoke supporting data.
Environmental compliance extends to closed solvent handling, with solvent recovery rates reported internally for all major process lines. Ongoing assessments target reduction of aromatic solvent use, favoring alternatives when available without affecting API quality attributes. Plant utilities monitor energy and water use, seeking cost and waste reductions throughout the campaign, supporting continuous progress toward lower carbon intensity per kilogram of final product.
Direct technical support draws on internal specialists in synthesis, QA/QC, downstream processing, and formulation science. Consultation spans impurity identification, validation document sharing (NMR, HPLC, particle characterization), and problem tracing for specific grade or lot performance. For uncommon analytical or application scenarios, cross-functional teams coordinate customized investigations based on customer submittals.
Manufacturing support responds to variable requirements for granule size, surface area, and flow properties. Application engineers work alongside formulators at pharmaceutical companies, providing processing history, scale-up advice, and reprocessing guidance when performance deviates from validation runs. In dedicated projects, teams offer trial batch samples for initial formulation, complemented with material safety and processing advisories suitable for those application specifics.
Quality and reliability form the core of after-sales commitments. Every lot ships with full batch traceability, analytical release reports, and supporting documentation as per purchase contract. In the event of customer-reported deviations, root-cause analysis teams respond within predetermined windows, delivering both production records and corrective action summaries. Ongoing customer interactions feed back into process improvements, strengthening the reliability of future batches.
Our facility produces Diflunisal using controlled, reproducible processes designed for B2B supply chains. Starting with pharmaceutical-grade raw materials, every operation—from chemical synthesis through isolation and purification—has been engineered for large-batch output, minimizing variability across product lots. Automated process controls, with in-line monitoring, ensure all critical process parameters meet set targets throughout each production run.
Manufacturers use Diflunisal in nonsteroidal anti-inflammatory drug (NSAID) formulation. Bulk pharmaceutical production facilities incorporate Diflunisal as an active ingredient for tablets, powders, and suspensions. Fine chemical producers also integrate this compound in custom synthesis for specialty intermediates. Across each segment, users depend on steady input from reliable large-scale sources with proven analytical documentation.
Each batch undergoes multi-stage release, with both in-process and final product testing by trained in-house analysts. Chromatography, titration, and spectroscopic methods verify assay value, impurity profile, particle size distribution, and moisture levels. Dedicated stability chambers track batch samples to confirm shelf life matches the required specification. Buyers can access batch-level certificates that link directly to analytical reports generated at our production site.
Bulk Diflunisal leaves our plant in secure, tamper-evident containers engineered for industrial distribution. Packaging specialists select drum linings and bag materials that match chemical compatibility and storage duration requirements. For high-throughput manufacturing lines, packaging options support efficient material transfer, whether for drum-dispensing or automated handling. Every shipment follows strict documentation from production to warehouse to freight handover, supporting compliance and traceability.
Process engineers and technical managers may require consultation on formulation, scale-up, or regulatory documentation for their Diflunisal applications. Our technical team assists with detailed product dossiers, impurity maps, and historical batch data, helping manufacturers maintain approval processes and audit readiness. Production chemists and formulation scientists have direct access to staff with hands-on process knowledge—not just sales or documentation personnel.
Direct purchase from a primary source translates to stable supply and competitive cost structure for downstream partners. Procurement teams benefit from volume agreements and reliable year-round output. Distributors serving regulated markets gain confidence from transparent documentation and proven batch reproducibility. For manufacturers integrating Diflunisal into finished product lines, the ability to trace quality from raw input through every step of the process is non-negotiable. Our approach ensures each ton of material supports high-throughput industrial requirements without loss of specification or compliance risk.
Inside our facilities, we deliver Diflunisal by shaping well-controlled chemical processes, tracking each lot from raw material to finished solid. This commitment lets us speak directly about what goes on at the molecular level. Diflunisal operates as a nonsteroidal anti-inflammatory drug, or NSAID, with its activity rooted in blocking specific enzymes — cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2). By controlling these enzymes, the compound restricts the conversion of arachidonic acid into prostaglandins. This inhibition directly translates to less local inflammation, pain, and fever, since prostaglandins act as chemical messengers that amplify these physiological responses.
We have seen over decades in our synthesis and QC processes that purity and consistency strongly influence pharmacological outcomes. Suboptimal batch control can introduce impurities affecting this inhibition pathway, which underscores why we invest so heavily in validated, reproducible synthesis — our investment shows up in predictable pharmacodynamics batch after batch.
Diflunisal earned its place on the clinical shelf by delivering relief from various mild to moderate pains and inflammatory conditions. The bulk of the global output heads for applications such as osteoarthritis, rheumatoid arthritis, and musculoskeletal disorders. We tailor our production to serve manufacturers of both prescription and over-the-counter finished formulations, aware that patient needs drive repeating orders for a reliable active ingredient profile.
Where it stands out is its extended duration of action. The salicylic acid structure allows for slower elimination compared to many other NSAIDs, which means dosing schedules often run less frequently. Pharmacies and hospitals report more consistent patient adherence with Diflunisal-based therapies for chronic joint or muscle pain partly for this reason.
Our technical team controls every process parameter — starting from solvent selection, reaction monitoring, and final crystal precipitation. We do not ship a single drum or package until internal HPLC and identity tests confirm both high API yield and absence of unwanted byproducts. Our industrial reactors operate with real-time temperature and pH controls, reflecting over thirty years of process refinement for this salicylic acid derivative.
We also receive feedback from formulation partners on granule size, flow, and compressibility. These insights enable us to fine-tune operational details and guarantee repeatable tablet pressing or capsule-filling downstream. Effective communication between technical, regulatory, and commercial divisions ensures compliance with evolving global standards — we integrate every update into our SOP documentation.
From a manufacturer’s perspective, maintaining reliable Diflunisal output means constant vigilance on multiple fronts. Raw material integrity, batch consistency, proper containment of dust or vapors, and adherence to environmental discharge limits factor into daily operations. Each challenge presents an opportunity to reinforce our controls, upgrade instrumentation, and strengthen our partnership with finished dosage manufacturers.
We recognize market demands for higher purity, traceability, and documentation with every contract. Our team strives to preempt supply volatility by diversifying upstream raw material sources and planning maintenance cycles that minimize unexpected line downtime. We prioritize transparency for clients who demand precise technical documentation, impurity profiling, and full traceability across production lots.
Our firm takes pride in delivering a Diflunisal active ingredient that ends up in reliable pain management solutions. We believe that excellent process chemistry leads directly to patient safety and positive therapeutic outcomes. Clients rely on our commitment to batch-level reproducibility, robust technical support, and on-time fulfillment as they develop and supply finished drug products to healthcare professionals worldwide.
In bulk manufacturing, clarity about minimum order quantities and realistic lead times matters most, especially for active pharmaceutical ingredients like diflunisal. As a producer with full control over the production chain—from raw materials sourcing to final testing—decisions about batch size, delivery, and scheduling rest squarely with our team and our facilities.
For diflunisal, our process infrastructure supports large, campaign-based batch production. We set our minimum order quantity based on both technical efficiency and regulatory best practices. The threshold exists to ensure two things: every order passes economic viability, and product stewardship never lapses. For this API, standard minimums commonly start at the 100 kg level for bulk orders. These volumes allow us to optimize reactor usage and minimize unnecessary material loss.
Shifting to smaller orders can disrupt planning, reduce yield, and drive up per-unit costs. Even during periods of fluctuating demand, we maintain these minimums to preserve quality and compliance. Buyers with requirements above 100 kg gain the most value from our scale, and our team can discuss split shipments or phased releases for logistics scheduling.
Lead time hinges on multiple interconnected steps—from raw material qualification and synthesis, to purification, and extensive analytical testing. For diflunisal, our typical lead time for a standard 100 kg to multi-tonne order runs between six and ten weeks, calculated from order confirmation and receipt of advance payment or terms agreement. This timeframe includes all relevant in-process controls, multiple quality control checks, and the preparation of batch documentation.
Even with robust supply chain relationships, occasional disruptions in precursor availability can affect scheduling. Our project management team works to preempt shortages through supplier diversification and scheduled stocking of key upstream chemicals. If customers have ongoing requirements, we often encourage scheduled orders or rolling forecasts to secure production slots in advance. Open communication about future demand lets us keep lead times consistent and adjust capacity when planning plant maintenance or changeovers.
Every kilogram of diflunisal leaves our site accompanied by a certificate of analysis and full traceability data. Quality assurance is rooted in careful source selection, vetted production partners for precursors, and batch release testing performed by our in-house laboratories. We never cut corners for speed; we operate under cGMP guidelines and external audits keep our systems accountable. For customers requiring tailored documentation—such as updated DMFs or country-specific dossiers—our regulatory affairs professionals work in tandem with production to prepare compliant files without extending manufacturing lead times.
We combat delays by employing preventive equipment maintenance, maintaining core raw materials on hand, and using digital tracking for incoming and outgoing shipments. Agile scheduling systems allow us to align order intake with continuous production slots. Customers benefit from transparent communication—every inquiry receives a clear production calendar and, upon request, updates through each manufacturing milestone. In rapid market shifts or during regulatory disruptions, we prioritize existing clients under framework agreements, ensuring stability in supply chains even in volatile periods.
A stable relationship with the original manufacturer supports confidence for buyers. Orders meet agreed specifications, and shipment documentation matches every lot. We do not speculate in the market or fragment inventories—buyers receive direct-from-factory material at the source of production, eliminating ambiguity and reducing turnaround variance.
Our day-to-day experience producing and shipping Diflunisal has shown how attention to proper storage matters all the way from the factory to the end user. Diflunisal maintains physical stability under standard temperature and humidity; as a manufacturer, we always pack each batch into sealed fiber drums or high-barrier bags, safeguarding the powder from light and ambient moisture. Consistent with established pharmaceutical protocols, we select inner polyethylene liners and moisture-absorbent materials for every shipment leaving our facility. Exposure to direct sunlight or excess humidity corrodes quality; our factory warehouses remain dry, shielded, and clearly labeled, and we expect the same from logistics partners.
Chemical compatibility is critical. Despite Diflunisal being classified as stable and non-volatile, we keep it away from oxidizing agents, acids, and foodstuffs to prevent cross-contamination. Storage areas are swept and isolated from strong-smelling chemicals. During transportation, vehicle interiors must remain cool, clean, and free from sharp temperature fluctuations. Open flames and sources of heat have no place near pharmaceutical-grade inventory. These precautions are rooted in decades of handling various benzoic acid derivatives.
Direct manufacturing oversight includes full responsibility for legal documentation tied to each shipment. Regulatory agencies closely monitor the international movement of active pharmaceutical ingredients (APIs), such as Diflunisal, to guard against diversion and adulteration. We never cut corners on batch-specific Certificates of Analysis (COA), which confirm compliance with pharmacopeial standards. Safety Data Sheets (SDS) travel with every batch, providing short- and long-term safety guidelines in case of incidental exposure or spillage. Our serial batch numbers ensure traceability from raw materials through production and on to the destination.
Importing Diflunisal demands advance planning. Standard shipping documentation includes the commercial invoice, packing list, and airway bill or bill of lading. Each country enforces its own pharmaceutical customs protocol. For many ports, authorities expect Drug Master File (DMF) information, Good Manufacturing Practice (GMP) statements, and sometimes import licenses specific to the consignee. Our compliance team stays in regular contact with importing agents and regulatory officials, updating our document library in step with new or revised standards. Because we control the whole production chain, all technical and registration dossiers reflect actual manufacturing conditions—no guesswork, no shortcuts.
Problems can arise if cargo handlers misunderstand the nature of bulk chemical APIs. Mislabeling, improper stacking, or temperature excursions during transport can easily damage quality and delay import clearance. We proactively arrange technical briefings with forwarders and add clear signage inside every shipping container. For air freight shipments, we review International Air Transport Association (IATA) regulations and specify “non-hazardous pharmaceutical raw material” status, which accurately captures the safe profile of Diflunisal for routine handling.
For end users and regulatory authorities, documentation and consistent storage act as mutual protection. Our manufacturing oversight has stopped more than one potential mix-up before delivery—sometimes something as small as a missing customs stamp can spark unnecessary inspections. We contribute technical detail directly to the registration process wherever a customer seeks market authorization, closing information gaps from the factory’s perspective.
Our goal is to match product performance to regulatory expectation—never treating storage, labeling, or paperwork as an afterthought. Whether shipping single drums or full containers, we apply the same disciplined protocol that has guided our team since we first began manufacturing Diflunisal and its precursors. That is the only way to protect our partners’ investments and support patient safety at the end of a very real supply chain.
For product inquiries, sample requests, quotations or after-sales support, please feel free to contact me directly via sales9@bouling-chem.com, +8615651039172 or WhatsApp: +8615651039172
